Acute Porphyria Drug Database

B06AC02 - Icatibant
Propably not porphyrinogenic
PNP

Rationale
Icatibant is not metabolized by CYP enzymes. Nausea is a common side effect that can be potentially porphyrinogenic through reduction in caloric intake.
Therapeutic characteristics
Icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). A common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Other common side effects are dizziness and headache.
Metabolism and pharmacokinetics
Icatibant is metabolized by proteolytic enzymes. Elimination half-life is 1-2 hours. In vitro studies have shown that icatibant is not metabolized by oxidative metabolic pathways and it is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4, or and inducer of CYP1A2 and CYP3A4 (SPC).

References

  1. Summary of Product Characteristics
  2. Norwegian medicines agency. Summary of Product Characteristics (SPC). Icatibant. #3080

Similar drugs
Explore alternative drugs in similar therapeutic classes B06A / B06AC or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙